IgM ANTIBODY TO THE HEPATITIS B CORE ANTIGEN IN ACUTE HEPATITIS DETERMINED BY SPRIA ‐ DIAGNOSTIC VALUE

Authors:

Abstract
A solid phase radioimmunoassay (SPRIA) was developed for the detection of anti-HBc [antibody to hepatitis B core antigen] IgM. The assay proved sensitive and easy to perform and rheumatoid factor did not affect the test results. Anti-HBc IgM titers were followed in consecutive samples from 15 patients after uncomplicated acute hepatitis B. In the acute phase the anti-HBc IgM titers ranged from 10-5-10-7 (mean 10-6.4). One yr after onset of disease, 10 of the 15 had titers < 10-4 and between 2-3 yr after onset most patients had titers 10-3. Anti-HBc IgM titers were determined in 6 episodes of acute hepatitis B, all HBsAg [hepatitis B surface antigen] negative but anti-HBc positive in the 1st samples obtained (within 8 days) and developing anti-HBs [antibody to HBsAg] during convalescense. Acute phase anti-HBc IgM titers in these patients ranged between 10-5.5-10-7 (mean 10-6.5) and were thus identical with HBsAg positive cases. When acute phase sera from 168 episodes of acute hepatitis primarily classified as non-A, non-B, were tested for anti-HBc IgM titers > 10-5, sera from 13 episodes were positive and in 7 of these hepatitis B diagnosis could be confirmed by rising anti-HBs titers in convalescense. Sera from 4 of the 13 patients contained HBeAg [hepatitis B e antigen], which was thus demonstrated in the absence of HBsAg. Thus, testing for anti-HBc IgM is seemingly important for a true non-A, non-B diagnosis.

This publication has 22 references indexed in Scilit: